Keywords: ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; EMN, eruptive melanocytic nevi; Ph+, Philadelphia chromosome–positive; TKI, tyrosine kinase inhibitor; adverse effects; chronic myeloid leukemia; drugs; eruptive melanocytic nevi; ponatinib.